LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,700 | -16.3% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q2 2023 | $21,150 | -6.0% | 15,000 | 0.0% | 0.01% | -14.3% |
| Q1 2023 | $22,500 | +28.2% | 15,000 | 0.0% | 0.01% | +16.7% |
| Q4 2022 | $17,550 | +3.2% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $17,000 | -29.2% | 15,000 | 0.0% | 0.01% | -25.0% |
| Q2 2022 | $24,000 | +4.3% | 15,000 | 0.0% | 0.01% | +33.3% |
| Q1 2022 | $23,000 | -37.8% | 15,000 | 0.0% | 0.01% | -33.3% |
| Q4 2021 | $37,000 | -2.6% | 15,000 | 0.0% | 0.01% | -10.0% |
| Q3 2021 | $38,000 | -11.6% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $43,000 | +7.5% | 15,000 | 0.0% | 0.01% | +9.1% |
| Q1 2021 | $40,000 | +53.8% | 15,000 | 0.0% | 0.01% | +37.5% |
| Q4 2020 | $26,000 | +85.7% | 15,000 | 0.0% | 0.01% | +60.0% |
| Q3 2020 | $14,000 | +7.7% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $13,000 | +8.3% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q1 2020 | $12,000 | -7.7% | 15,000 | 0.0% | 0.01% | +50.0% |
| Q4 2019 | $13,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 5,036,720 | $14,354,000 | 4.77% |
| BROADWOOD CAPITAL INC | 34,005,379 | $96,915,000 | 4.33% |
| Prescott General Partners LLC | 1,851,851 | $5,278,000 | 0.17% |
| Raffles Associates | 43,590 | $124,000 | 0.10% |
| Laidlaw Wealth Management LLC | 123,730 | $353,000 | 0.09% |
| DCF Advisers, LLC | 74,500 | $212,000 | 0.08% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $128,000 | 0.07% |
| Strategic Wealth Investment Group, LLC | 64,232 | $183,000 | 0.06% |
| Paradigm, Strategies in Wealth Management, LLC | 19,775 | $56,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $137,000 | 0.05% |